The galectin-3 valuein nitrosative stress assessment incells of heart atpatients withchronic heart failure



Cite item

Full Text

Abstract

In the article the results of definition of plasma level galectin-3 and indicators nitrosative stress in patients with chronic heart failure of ischemic etiology. Data of correlation analysis of the contents of 3-nitrothyrosinum, extracellular superoxide dismutase and plasma level galectin-3 in the examined patients are presented.

About the authors

I I Berezin

I I Berezin

References

  1. Фомин И.В., Беленков Ю.Н., Мареев В.Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН // Сердечная недостаточность - 2006-Т7-№1-С.4-7.
  2. Беленков Ю. Н., Мареев В. Ю., Агеев Ф.Г. Хроническая сердечная недостаточность. Избранные лекции по кардиологии / Ю.Н. Беленков, В.Ю. Мареев, Ф.Г. Агеев. - М.: ГЭОТАР-Медиа, 2006 - 432с.
  3. Агеев Ф.Г., Азизова А.Г. Галектин-3 - новый биохимический маркер сердечной недостаточности // Сердечная недостаточность - 2011-Т12-№2-С.108-114.
  4. Boer R.A., Voors A.A., Muntendam P., et al. Galectin-3: a novel mediator of heart failure development and progression // Eur.J.Heart Fail-2009-v11-Р.811-817
  5. Shah R.V., Chen-Tournoux A.A., Picard M.H. et all. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure // Eur. J. Heart Fail - 2010 -№8- Р.826-832.
  6. de Filippi C.R., Felker G.M. Galectin-3 in heart failure-linking fibrosis, remodeling, and progression // US Cardiology - 2010;-7(1)- Р.67-70.
  7. Almkvist J., Karlsson A. Galectins as inflammatory mediators // Glycoconj J. 2004-v19- Р.575-581.
  8. Дубинина Е.Е., Туркин В.В., Бабенко Г.А., Исаков В.А. Выделение и свойства супероксиддисмутазы плазмы крови человека // Биохимия - 1992 - Т57-№ 12-C.1892-1901; Lu Z., Xu X., Hu X., Extracellular Superoxide Dismutase Deficiency Exacerbates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction // Hypertension - 2008 -v.51(1)- Р.19-25.
  9. Shah R.V., Chen-Tournoux A.A., Picard M.H. et all. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure // Eur. J. Heart Fail - 2010 -№8- Р.826-832; Sharma U.C., Pokharel S., Brakel T.J. et all. Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction // Circulation - 2004 v110- Р.3121-3128.
  10. MacKinnon A.C., Farnworth S.L., Hodkinson P.S. et all. Regulation of alternative macrophage activation by galectin-3 // The J. Immunology - 2008-v180- Р.2650-2658.
  11. Boer R.A., Yu L., Veldhuisen D.J. Galectin-3 in cardiac remodeling and heart failure // Curr. Heart Fail. Rep. - 2010-v7- Р.1-8.
  12. Lok D.J., van der Meer P., de la Porte PWB, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study // Clin. Res. Cardiol. 2010-v99(5)- Р.323-358.; Nabeebaccus A., Zhang M., Shah A.M. NADPH oxidases and cardiac remodelling // Heart Fail. Rev. - 2011-v16-Р.5-12.
  13. Hare J.M., Stamler J.S. NO/redox disequilibrium in the failing heart and cardiovascular system // Clin. Invest. 2005-v115- Р.509-517.
  14. Ungvari Z., Gupte S.A., Recchia F. et all. Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart Failure // 2005-v20- Р.201-210.
  15. Suzuki Y., Inoue T., Yoshimaru T., Ra C. Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition // Biochim Biophys Acta. - 2008-v1783(5)- Р.924-934.
  16. Almkvist J., Karlsson A. Galectins as inflammatory mediators // Glycoconj J. 2004-v19- Р.575-581.
  17. Меньщикова Е.Б. Окислительный стресс. Патологические состояния и заболевания / Е.Б. Меньщикова, Н.К. Зенков, В.З. Ланкин и др. - Новосибирск: АРТА, 2008. - 290с.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2012 Berezin I.I., Berezin I.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies